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During the last 10 years several muscular dystrophies within the group of distal myopathies have been clarified as to the molecular genetic
cause of the disease. Currently, the next steps are carried out to identify the molecular pathogenesis downstream of the gene defects. Some early
ideas on what is going on in the muscle cells based on the defect proteins are emerging. However, in no single distal muscular dystrophy these
efforts have yet reached the point where direct trials for therapy would have been launched, and in many distal dystrophies the causative gene is
still lacking. When comparing the gene defects in the distal dystrophies with the more common proximal muscular dystrophies such as
dystrophinopathies or limb-girdle muscular dystrophies, there is a striking difference: the genes for distal dystrophies encode sarcomere proteins
whereas the genes for proximal dystrophies more often encode sarcolemmal proteins.
© 2006 Elsevier B.V. All rights reserved.Keywords: Muscular dystrophy; Distal dystrophy; Distal myopathy; Molecular genetics; Molecular pathogenesis; Molecular biology1. Introduction
Distal dystrophies—distal myopathies are defined as
inherited primary muscle disorders characterized by progressive
muscular weakness and atrophy beginning in the hands,
forearm, lower legs or feet [1]. Distal myopathy has prevailed
as the main term for historical reasons even if the disorders in a
clinical sense are muscular dystrophies.
The different entities of this category have all first been
determined as new disorders based on their clinical findings
(Table 1). During the last 10 years, the molecular genetic
background of the different entities has been resolved in most of
the major forms. This significant progress has shown that many
gene defects underlying distal dystrophies may cause not only a
distal presentation but a variety of clinical phenotypes [1].
Eventually, when most myopathies/dystrophies have been
defined by their gene defect, distal myopathy as a category of
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doi:10.1016/j.bbadis.2006.08.005currently emerging molecular genetic definition may in turn be
replaced by categories defining distinct molecular biological
functions and pathways disrupted by the gene defects.
The first well documented large family published as a distal
myopathy was reported in 1943 [2]. Six patients in a dominant
family with 12 affected males had distal leg weakness with
onset in early adulthood. Later studies in this family showed
desmin accumulations in muscle biopsy and a mutation in the
desmin gene [3]. The change of classification in this family,
from distal myopathy to desminopathy, illustrates current
developments following progress in molecular genetics.
In this review the traditional grouping of the different entities
based on clinico-genetical presentation has given way to a new
molecular biology type of basic approach in order to facilitate
the association of the basic clinical problem with the biological
and functional units of the muscle cell. However, our current
understanding of the molecular pathophysiology of these
disorders is still highly incomplete and only emerging. Many
defects involve large sarcomere proteins and hypotheses on how
these defects could be overcome by therapeutic interventions
are, at present, very vague. In disorders with dominant gain of
function and abnormal accumulations of protein, silencing the
Table 1
Distal myopathies with genetic definition
Type OMIM # Refer. Onset CK Muscle pathology Genetics
Age Initial weakness Family Gene and locus
Laing early onset distal
myopathy MPD1
#160500 1–25 Anterior lower leg 1–8× Type 1 fiber atrophy in











Udd distal myopathy TMD #600334 >35 Anterior lower leg 1–4× Dystrophic, rimmed
vacuoles
AD Titin TTN, 2q31
Distal onset in telethoninopathy Vainzof personal
communication
early Lower leg, anterior 3–10× Rimmed vacuoles AR Telethonin 17q
Desminopathy MFM
(myofibrillar myopathy)









40–60 Lower legs and hands 1–3× Rimmed and non-rimmed










40–60 Lower legs and hands 1–3× Rimmed and non-rimmed












Distal Caveolinopathy #601253 early hands 3–10× Reduced caveolin-3 AD CAV3
Miyoshi myopathy MM #254130 15–30 Posterior lower leg, calf 10–100× Dystrophic AR Dysferlin 2p13
Nonaka distal myopathy
DMRV/ hIBM
#605820 15–30 Anterior lower leg 1–5× Rimmed vacuoles AR GNE 9p1–q1
Welander distal
myopathy WDM




vocal cord and pharyngeal
signs MPD2
#606070 35–60 Asymmetric lower leg and
hands+dysphonia
1–8× Rimmed vacuoles AD 5q31
Distal myopathy with pes
cavus and areflexia







Williams 10–40 posterior− lateral lower leg 1–2× Myopathic−dystrophic AD 12 genetic loci
excluded
Adult onset distal myopathy
MPD3
Mahjneh >30 Hands or anterior lower leg 1–4× Dystrophic, rimmed
vacuoles,+ eosinophilic
inclusions




25–50 Posterior lower leg, calf 1–10× Myopathic−dystrophic AR and
sporadic
Some 10q
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look like an option.
Distal muscle weakness and atrophy is sometimes the
presenting symptom and sign in myopathies that are mainly
characterized by other major findings. These conditions are
noted only briefly. The basic molecular biology of dysferlino-
pathy is covered in the LGMD-review and GNE-associated
hereditary inclusion body myopathy (hIBM) is presented in the
corresponding review.
2. Distal dystrophies caused by defects in structural
components of the sarcomere
Defects in the excitation–contraction coupling machinery of
the A-band part of the sarcomere generally cause cardiomyo-
pathy (personal comment). Genes and proteins involved include
myosin heavy and light chains (MHC and MLC proteins),
myosin binding protein C (MYBP-C) and titin. However, if the
defects lie outside the A-band region of these proteins, other
phenotypes will develop (Fig. 1A). Also mutations in proteinsor particular parts of proteins in the Z-disk and I-band of the
sarcomere may cause cardiomyopathy.
Some distal dystrophies are very early onset, such as
myosinopathy, whereas others are late onset or even very late
onset, such as titinopathy or myotilinopathy. In the early onset
forms the defect in target muscles is possibly congenital
although clinical signs, such as drop foot, are usually observed
when patients start to walk. This type of very early onset of
muscle weakness is suggestive of developmental/constructional
abnormalities in contrast to the late onset disorders, which
develop after long time usage as a deficiency of maintenance
and an imbalance between damage and repair.
2.1. Thick filament disorders—myosinopathies
Mutations located in the tail region of the slow myosin
heavy chain gene MYH7 are the cause of early onset dominant
distal myopathy (Laing myopathy) [4,5] (Fig. 1A). A number
of mutations have been reported in this region between residues
1500 and 1729, with preference for deletions or insertions of
Fig. 1. Schematic drawing of the structural proteins of the sarcomere and proteins involved in distal myopathies indicated (A). Below in B the same schematic
sarcomere structure detailed for titin and known mutations in c-terminal titin causing TMD titinopathy (Udd myopathy) disease (B).
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in the alpha-helix. For example, the K1617del mutation has
occurred independently in different populations and also ‘de
novo’ in one of the studied families, forming a hot spot
mutation [6]. Moreover, this location in the tail of slow MHC
includes the domain defined to interact with myomesin and it is
just N-terminal of the defined domain (between residues 1815
and 1831) for interaction with c-terminal titin [7]. The tails of
individual MHC molecules are physically located in the M-line
of the sarcomere (see below distal titinopathy), which is of
interest regarding the phenotype, but the exact functional
molecular consequences of the mutations in this part of the
myosin filament are not known. Muscle fibers in affected
muscles undergo atrophy more than fiber necrosis and type 1
fibers, besides atrophy, show reprogramming towards hybrid
expression of different myosins [6]. Mutations in the ultimate
c-terminus of slow MHC cause another phenotype: hyalinebody myopathy, with variable clinical presentation and with
unstructured myosin deposits in the hyaline bodies in the
myofibers [8]. Mutations in the proximal neck–head part and
different mutations in the rod domains of slow MHC may cause
cardiomyopathy [9,10].
2.1.1. Clinical phenotype
Clinically distal myosinopathy is to some extent similar to
the first ever reported distal myopathy; Gowers' description of
a patient in 1902 [11,12]. Weakness begins in the lower leg
anterior compartment between 1 and 25 years of age with a
characteristic hanging big toe-sign and severe atrophy and
weakness of neck flexors, the sternocleidomastoid muscles
(Fig. 2A). The disease progression is slow, eventually
resulting in weakness of finger flexors, shoulder, trunk, facial
and tongue muscles. Scoliosis and tendon contractures, mainly
in the ankles, are common. Cardiomyopathy has rarely been
Fig. 2. Legs of a 42-year-old male patient with mutation in slow myosin heavy chain MYH7 gene causing MPD1 myosinopathy (Laing myopathy), showing the
‘hanging big toe’ sign but clinically not much visible tibial anterior atrophy despite total loss of function (A). CTscan of lower leg muscles in a 12-year-old male patient
with MYH7 mutation showing total replacement by fat and connective tissue in anterior compartment muscles and also severe changes in soleus muscles bilaterally
(B). Serial sections of end stage pathology muscle tissue from tibial anterior muscle (same patient as panel B) showing just one atrophic muscle fiber expressing slow
myosin (C), and all other highly atrophic fibers express fast myosin (D), where the proportions normally are the opposite in this particular muscle.
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encountered.
2.1.2. Laboratory findings and muscle pathology
Serum CK is slightly elevated or normal, and EMG shows
early-recruiting short duration, low amplitude and polyphasic
motor unit action potentials. Spontaneous activity was found in
the more severely affected muscles, without signs of neuropathy
[12]. Muscle imaging is highly suggestive of the diagnosis
showing, besides overall small muscle mass, severe changes of
degeneration in the anterior tibial muscles (Fig. 2B) and, at
advanced age, also lesions in posterior calf and the proximal
thigh muscles. The early atrophy of sternocleidomastoid
muscles can also be captured [6].
On muscle biopsy rimmed or other vacuoles were found in a
minority of the reported biopsies [6,14]. Findings in more
affected anterior tibial (TA) muscle show very distinct
pathology with bimodal fiber size distribution: large numberof highly atrophic tiny fibers scattered and in groups in portions
with end stage pathology, simulating large group atrophy.
Practically all fibers express fast myosin, whereas normally
only a small minority of fibers is type 2 fibers and 80–90% may
be slow type 1 fibers in TA (Fig. 2C–D). In distal myosinopathy
almost all type1 fibers expressing slow myosin are highly
atrophic group and they also express fast myosin, suggesting a
complete reprogramming of fiber type specifications due to the
slow myosin MYH7-gene defect. [6].
2.2. Thin filament disorders—nebulinopathies
The hallmark of defects in thin filament proteins actin,
troponin, tropomyosins and nebulin is congenital myopathy,
and even more specifically: nemaline myopathy [15]. Nemaline
rods occurring in myofibers on light and electron microscopy is
a diagnostic corner stone in the differential diagnostics of
congenital myopathies, and if present, they direct molecular
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known to cause nemaline myopathy. So far, there is no good
pathophysiological explanation why thin filament proteins and
not other sarcomere proteins cause this specific type of protein
aggregates. Possibly some intrinsic property of the thin filament
structure, lacking in the other filament systems, may account for
nemaline type of aggregation if one of the basic components is
defect and harms the correct turnover.
However, not all genetic defects in the thin filament
proteins cause nemaline myopathy. We have recently
identified recessive missense mutations in nebulin (NEB)
gene which do not cause nemaline rods to occur in affected
muscle cells, but they cause a recessive distal myopathy
[manuscript in preparation]. Interestingly, exactly the same
missense mutations induce nemaline rod pathology when they
combine with truncating or splicing mutations in compound
heterozygous patients, in the same way as with other than
missense mutations on both chromosomes.
2.2.1. Clinical phenotype and laboratory findings
Mutations in nebulin are a well known cause of autosomal
recessive congenital nemaline myopathy [16]. Besides general-
ized weakness and muscle atrophy of variable severity, the distal
muscles are usually more involved than the proximal ones. In
our distal nebulin myopathy patients with missensemutations on
both chromosomes, the clinical and the myopathology pheno-
type is clearly different. Extensor muscles of hands and feet are
severely affected, but the progression is very mild, walking is
preserved and patients do not have major disability in adulthood.
Muscle imaging reveals selective degeneration in the anterior
tibial muscles, EMG is myopathic and CK is normal or mildly
elevated. Muscle biopsy shows scattered and grouped atrophic
fibers. The reason for the disorder not to have been identified
earlier as nebulinopathy is that the homozygous missense
mutations do not produce nemaline rods on light microscopy,
despite multiple biopsies in some cases (Udd 2006, personal
communication). Careful re-analyses of semi-thin sections and
electron microscopy in our patients with homozygous mutation
in exon 155 revealed rare small rod type changes, but on routine
light microscopy no rods could be identified. Homozygous
missense mutation in exon 121 caused disintegration of
sarcomere structure but absolutely no rods even on electron
microscopy in multiple biopsies from the same individual.
Molecular diagnosis of this group of patients is currently
laborious considering the large size of the gene.
2.3. Third filament system—titinopathies
The first identified genetic defect underlying autosomal
dominant distal dystrophy was mutations in c-terminal titin that
cause tibial muscular dystrophy (TMD, OMIM #600334, Udd
myopathy) [17,18]. Titin is the largest single polypeptide
protein in nature and each molecule spans over one half of the
sarcomere from Z-disk to M-line, interacting both with thin
filaments and thick filaments (Fig. 1A–B). During myofibrillo-
genesis titin is expressed before the other filament systems of
the sarcomere and is thought to form a scaffolding ruler for thehighly organized structure of the sarcomere [19,20]. Titin
interacts repeatedly with myosin filaments in the A-band region
and through the interface of MYBP-C, causing strong positional
fixation of the contractile system and keeping the myosin thick
filaments always centered in the sarcomere [21]. In the middle
of the sarcomere, in the M-line portion, titin has less modular
and more complex sequence properties, including a kinase
domain, interaction domains for myomesin and unique
sequences with unknown functions [22]. In the M-line,
c-termini of titin molecules from both flanking Z-disks meet
and probably overlap. Since n-terminal titins also overlap each
other from neighboring sarcomeres in the Z-disk, titins in
consecutive sarcomeres may form a continuous filament struc-
ture extending from one sarcomere to the other (Fig. 1A–B).
Recently, we have identified M-line titin, i.e. the kinase domain
(Fig. 1B), as a sensor of mechanical contraction activity in the
myofiber with a physically interacting signaling complex of
proteins [23]. This signaling complex includes MURF2, which
in the normal state of muscle activity stays in the complex in the
M-line, but dissociates and shuttles to the nucleus where it
inactivates the activity of the transcription factor SRF, if muscle
activity is blocked chemically or by denervation[23].M-line titin
thus seems to have important signaling functions for regulation
of transcription and turnover in relation to variable contractional
demands. One point mutation in the regulatory tail of the kinase
domain is able to totally disrupt the function of the signaling
complex and causes a severe dominant muscle disease HMERF
with respiratory failure [23].
2.3.1. Molecular genetics
In close proximity to the kinase domain in the periphery of
the M-line is the ultimate c-terminus of the titin molecule. In its
last domain, the Ig-like M10, encoded by the last exon of the
gene, Mex6, we found the first mutations in TMD distal
dystrophy (Fig. 1B) [17]. The mutation in Finnish patients,
FINmaj, is a complex in frame ins/del of 11 consecutive base
pairs exchanging four amino acids in M10 [17]. The protein,
however, is damaged beyond M10 since epitopes in the third
last domain M9 are not recognized by specific antibodies [17].
The mutant titin is incorporated in the sarcomeres shown by
immunohistochemistry with antibodies to different other parts
of the protein in homozygous mutant muscle, and mutant titin
seems to be intact up to the fourth last domain M8 (Fig. 1B).
In two unrelated French families a point mutation changing a
lysine to proline was found in the same last Mex6 exon [19].
Later a third mutation in the same last exon was found in a
Belgian TMD family [24], and more unpublished mutations,
also in the last Mex6 exon, have been identified in Spanish and
other French families (Udd, personal communication). These
mutations are available for diagnostic testing. In new unrelated
TMD patients searching for mutations by sequencing the last
Mex 6 exon may be productive.
2.3.2. Molecular pathomechanism of c-terminal
titinopathy—TMD
Even in homozygous mutant muscle the overall sarcomere
structure is intact on electron microscopy, suggesting no
Fig. 3. Lower legs of a 48-year-old male patient with FINmaj mutation in c-
terminal titin causing TMD titinopathy (Udd myopathy) showing clear atrophies
of the anterior compartment muscles with subsequent prominent ventral edge of
the tibial bone (A). CTscans of lower leg muscles in a 62-year-old female patient
with FINmaj mutation showing selective total replacement of all anterior
compartment muscles: tibialis anterior, extensors hallucis longus and digitorum
longus, with normal appearance of the other lower leg muscles (B). Hematoxylin
and eosin stained tibial anterior muscle biopsy from early stages of the disease in
a 42-year-old female patient with FINmaj mutation showing large variation of
fiber size, increased connective tissue and one atrophic fiber with rimmed
vacuolar change (C).
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The downstream chain of molecular events is, however, not
yet defined. It will be complex, because in the few rare
patients with homozygous FINmaj mutation the phenotype is
completely different: early childhood onset proximal limb-
girdle muscular dystrophy with loss of ambulation around age
25 (LGMD2J) [26,27]. Whereas in TMD, the muscle
involvement is focal and selective targeting first the tibial
anterior muscles, in LGMD2J the dystrophy is generalized
with replacement in all large muscles at the age when clinical
symptoms from weakness of ankle dorsiflexion start to
emerge in the heterozygous TMD [27]. This complete
difference may suggest that downstream molecular pathways
are partly different in TMD vs. LGMD2J.
The only established ligand of c-terminal titin is muscle
specific calpain-3, that is responsible for LGMD2A when
mutated [28,29]. In homozygous LGMD2J calpain-3 is severely
reduced [30], but not in heterozygote TMD muscle, indicating
that some other disrupted protein interaction may mediate
pathology later in life in the heterozygotes. Myosin heavy chain
(MYH7) tail region has been shown to interact with titin (see
above), but the interacting region on titin is not defined yet.
2.3.3. Clinical phenotype
The clinical findings present after age 35, selectively
involving the tibialis anterior and, in advanced stages, the
long toe extensor muscles [25] (Fig. 3A). Weakness at onset
may be asymmetric and progression is slow. Mild to moderate
proximal leg muscle weakness occurs after age 70 in a minority
of the patients, but patients rarely become wheel-chair bound
even at advanced age. Clinically, the sparing of short toe
extensors (extensor digitorum brevis) is an important finding to
make distinction from neurogenic foot drop. Unlike inWelander
distal myopathy (WDM), hand muscles are rarely affected in
TMD [25]. Despite this characteristic presentation, a recent
study of 207 mutation confirmed patients showed unexpected
variants of the phenotype in 9% of the patients [25].
2.3.4. Epidemiology
Recent studies have shown a high TMD prevalence in
Finland of more than 8/100,000 [27,31]. Patients are found all
over the country, although the origins of their families can be
traced back to the west coast region of middle Finland and to the
Savo-Karelia area of eastern Finland [25]. TMD has also been
identified in Sweden, Norway, Germany and Canada in
descendants of Finnish immigrants. Moreover, TMD families
have recently been identified in other populations without
connections to the Finnish background and with other mutations
in c-terminal titin in France, Belgium and Spain [24,32] (Udd
personal communication 2006), and there is no reason to
believe that titin mutations should be restricted to certain
populations.
2.3.5. Laboratory findings and muscle pathology
Patients with TMD have normal or mildly elevated CK [25].
In affected muscles EMG studies showed low-amplitude, short-
duration motor unit potentials on moderate activity [26].
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and occasional high-frequency and complex repetitive dis-
charges at rest may be obtained in clinically affected muscles. In
clinically unaffected muscles of the upper limbs polyphasic
potentials may be recorded [25].
CT and MRI provide accurate data on the selective
involvement of individual muscles in TMD. Changes of fatty
degeneration appear at the time of clinical weakness [33]. The
evolution of selective involvement over time is very distinct in
TMD. Together with the presenting weakness of ankle
dorsiflexion, fatty degenerative changes appear in the anterior
tibial muscle. After 10–15 years of symptoms, lesions usually
appear in the long toe extensor muscles, and in hamstring,
gluteus medius, and tensor fasciae latae muscles [33] (Fig. 3B).
Initially, the involvement may be asymmetric. Later, focal
lesions may appear in apparently asymptomatic muscles, such as
the soleus, when other unaffected muscles mask the loss of
power and prevent the lesion from being observed clinically
[33].
Muscle specimens in TMD reveal myopathic alterations,
including variation of fiber size, thin atrophic fibers, central
nuclei, structural changes within the fibers, endomysial
fibrosis, and fatty replacement in the end stage muscle [34].
Necrotic fibers, some showing phagocytosis, are rare in TMD.
Fiber type differentiation was normal, both major fiber types
being equally involved in the pathological process(Fig. 3C).
Many rimmed vacuoles were acid phosphatase positive, while
others were ubiquitin positive and, with rare exceptions, they
were not lined by sarcolemmal membrane proteins. Congo red
stains and immunohistochemistry for beta-amyloid and amy-
loid precursor protein were negative in TMD specimens
containing fibers with rimmed vacuoles, in contrast to sporadic
inclusion body myositis. Ultrastructural studies in TMD
revealed overall well preserved sarcomere structure, even in
the homozygote LGMD2J mutants. Focal cytoplasmic and
sarcomeric degradation products and occasional tubulofila-
mentous inclusions were encountered in the vacuolated fibers
[25]. Rimmed vacuoles in TMD are usually not membrane
bound and thus do not fulfill the morphological criteria of
autophagic vacuoles, even though the vacuolar space contains
numerous small vesicles compatible with lysosomal autophagic
components.
2.3.6. Telethoninopathy
The other name of this protein, T-cap, indicates its function as
capping titin molecules in the periphery of Z-disks, and
telethonin may thus be connected to the third filament functions
rather than characterized by its location to the z-disk region (Fig.
1). Telethonin is shown to be a substrate of the serine–threonine
kinase in c-terminal titin. In mature muscle these locations are
physically distant, suggesting either shuttling of telethonin or
phosphorylation regulation only temporarily during myofibril-
logenesis when c-terminal titin and the kinase is located also in
emerging Z-disk regions. No further molecular pathomechan-
isms are detailed on the effects of mutations in telethonin, which
usually are reported to cause a proximal LGMD2G phenotype,
but, in fact, many of the patients have more distal atrophies andweakness at onset [1]. Themyopathology is myofibrillar rimmed
vacuolar.
3. Defects in Z-disk proteins and distal muscular
dystrophies
Recent progress has delineated several genes that underlie
the muscle pathology characteristics of myofibrillar myopathy
(MFM): desmin, αB-crystallin, myotilin, ZASP and filaminC
(Fig. 1A) [35–37]. Patients with dominant myofibrillar
myopathy frequently present as distal myopathies [38–42].
There is a wide range of onset, patterns of muscle involvement,
and progression rates. Patients may have additional features
cardiomyopathy, respiratory muscle weakness, neurogenic
findings and even EMG myotonia. The pathology includes
accumulations of all these proteins irrespective of primary gene
defect, suggesting that these share molecular pathways involved
in actin dynamics organized by the Z-disk. Besides accumula-
tions of these proteins, congophilic amyloid products of
myofibrillar degradation and ectopic aggregation of dystrophin
and gelsolin appear in abnormal myofibers [35].
3.1. Desminopathy
Desmin is a muscle-specific cytoskeletal protein and belongs
to the type III family of intermediate filaments. Desmin
mediates attachments between the Z-disks of parallel myofila-
ments and provides attachments between Z-disk and mem-
brane-associated proteins to form a force-transmitting system
(Fig. 1A). One of the earliest reports on distal myopathy
described a very large autosomal dominant family with
branches both in Europe and in North America [2]. This family
later proved to have a mutation in the desmin gene [3]. What
properties exactly are lost or gained by the mutations that cause
desmin together with other Z-disk proteins to agglomerate in
desminopathy is not known. Transfection studies of some
mutations caused incorrect forming of desmin intermediate
filament network, induced the collapse of a pre-existing desmin
cytoskeleton, altered the subcellular distribution of mitochon-
dria, and led to abnormal cytoplasmic protein aggregates [43].
3.2. Myotilinopathy
Myotilin (myofibrillar protein with titin-like Ig domains) is a
57 kDa Z-disk component that interacts with alpha-actinin [44],
filamin-C, FATZ (calsarcin) [45], and actin [46] (Fig. 1A). It
also controls sarcomere assembly [47]. Myotilin contains a
serine-rich amino-terminal region (residues 28 to 124) with a
hydrophobic stretch (residues 57 to 79), two Ig-like domains
with considerable homology to certain Ig domains of titin
(residues 252 to 341 and 351 to 441), and a carboxy terminal
tail. The alpha-actinin binding site resides between myotilin
residues 79 and 150, and the filamin-C binding site is located in
the second Ig-like domain. Myotilin dimerizes via its C-terminal
half, which may be necessary for the actin-bundling activity.
Myotilin is strongly expressed in skeletal muscle and weakly in
cardiac muscle [48]. Intramuscular nerve fibers are stained with
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3.2.1. Molecular genetic findings
Several TTID missense mutations have been reported. In
2004, three novel mutations (S60C, S60F, and S95I) and the
previously identified LGMD1A S55F mutation were reported in
6 unrelated patients with myofibrillar myopathy [35]. In a
Spanish cohort of 13 patients, three of the known and two new
missense mutations were identified [50]. All these 6 mutations
are located in same region of the gene, the serine-rich exon 2
encoded domain, and many caused predominantly late onset
distal dystrophy.
Considering that the pathology in the family reported by
Penisson-Besnier et al. [51] resembled more that of myofibrillar
myopathies, the myotilin gene was a good candidate in this
family. Sequencing showed that a previously reported mutation
S60F [35], segregated completely with the affected patients in
the family and was not present in healthy individuals [52].
Interestingly, this is another muscle specific protein that in some
instances may cause a dystrophy with a predominant proximal
LGMD-phenotype (LGMD 1A) [53] and in others a very
pronounced distal affection [51].
3.2.2. Clinical example
Penisson-Besnier et al. described an autosomal dominant
French family with a very late onset of distal myopathy around
the age of 60 years [51]. Weakness and atrophy was more severe
in the posterior calf muscles than in the anterior lower legs
muscles at onset. Later the patients experienced progression to
proximal and upper limb muscles, although with retained
walking ability even into later age. Cardiomyopathy was not
observed in the patients.
3.2.3. Laboratory findings and muscle pathology
Muscle enzyme CK was either normal or mildly elevated.
EMG showed myopathic changes with fibrillations and
complex repetitive discharges. Muscle imaging confirmed the
clinical findings of extensive involvement of calf muscles
showing dystrophic fatty replacement and very mild proximal
leg muscle involvement. Histopathology of proximal upper
limb muscles showed a variety of pathological findings
including multiple large non-rimmed vacuoles, focal sarcoplas-
mic desmin reactive masses that stained darker on Gomori
trichrome, rimmed vacuoles, and IBM-like cytoplasmic and
nuclear filaments on electron microscopy [51]. Immunohisto-
chemistry revealed abnormal myotilin aggregations and less
pronounced ectopic expression of desmin, ZASP and aB-
crystallin in the same aggregations [52].
3.3. Zaspopathy
ZASP (Z-disk alternatively spliced PDZ-domain containing
protein) is a component of the Z-disc and has known interactions
with alpha-actinin (Fig. 1A) [36,54]. Further mechanisms by
which mutated ZASP causes such widespread disintegration of
the sarcomere structure are so far elusive, but most mutationsidentified to cause MFM pathology are located in the Zasp-like
motif encoded by exon 6, which is expressed in skeletal muscle
and primarily responsible for the alpha-actinin binding [54,55].
Mutations in the alternatively expressed cardiac exon 4 are
shown to cause cardiomyopathy [56]. Studies on mouse models
including knock-outs suggest that ZASP is required for striated
muscle function and maintenance during the stress of contrac-
tion, but not for initial formation of the Z-disk [57].
3.3.1. Clinical example
In 1974, an autosomal dominant family (Markesbery–
Griggs) with six patients affected by distal myopathy was
reported [58]. Weakness started in the anterior distal leg muscles
between 43 and 51 years of age, then spread to the intrinsic hand
and wrist extensor muscles, and eventually to the proximal limb
and trunk muscles. Facial, bulbar or respiratory muscles were
not involved. The disease progressed slowly, did not alter the
length of life, but caused loss of ambulation in senescence.
Cardiomyopathy was present in one of the patients.
3.3.2. Molecular genetics
Early linkage studies in this classical Markesbery–Griggs
family indicated the disorder could be linked to the titin locus
2q31 [59]. Extensive mutation search in the huge titin gene was
not productive and no mutations were detected. With the reports
of myotilin and ZASP mutations in subsets of myofibrillar
myopathy patients [35,36], these genes became candidates,
supported by the fact that muscle pathology had similarities to
myofibrillar myopathy. Sequencing of myotilin gave normal
results, whereas the previously reported C523G mutation
A165V in ZASP was identified as the cause of disease in the
family (Griggs et al. paper in progress 2006).
3.3.3. Laboratory findings and muscle pathology
Patients have normal or only slightly elevated CK [58]. EMG
studies showed low-amplitude, short-duration motor unit
potentials on moderate activity. Most patients have increased
insertional activity, frequent fibrillation potentials, and occa-
sional high-frequency and complex repetitive discharges at rest
[58].
Muscle biopsies reveal myopathic alterations, including
variation of fiber size, central nuclei, structural changes within
the fibers, endomysial fibrosis, and fatty replacement of muscle
[58]. Necrotic fibers, some showing phagocytosis, and fibers
with rimmed vacuoles are abundant. In addition, some fibers
contain single or multiple non-rimmed vacuoles whose contents
fail to stain for lipids or polysaccharides. Focal accumulation of
homogeneous, granular material blue-red with Gomori tri-
chrome was prominent in some fibers. Immunohistochemistry
showed excessive ectopic expression of myotilin with less
similar changes in desmin, aB-crystallin and ZASP in the
abnormal fibers. Early electron microscopy changes included
dilation and vacuolization of the sarcoplasmic reticulum and
streaming and disruption of the Z-disk. Clumps of Z-disk
material were found without the periodicity of nemaline rods
[60]. Sarcoplasmic masses composed of glycogen granules,
lipofuscin bodies, tiny vacuoles, degenerated myofilaments, Z-
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retrospect these alterations are well compatible with reported
changes in myofibrillar myopathy. The vacuoles are membrane-
bound and contain osmiophilic vesicles, granular membrane
structures, myeloid figures, and other products of cytoplasmic
degeneration and fit the morphological criteria of autophagic
vacuoles. They are frequently at the fiber periphery and
sometimes covered only by the basement membrane indicating
that they may undergo exocytosis.
Autopsy studies were conducted in two patients [58]. One
patient had clinical evidence of a cardiomyopathy with
cardiomegaly, congestive heart failure, and intractable tachyar-
rhythmias requiring pacemaker implantation. At autopsy there
was diffuse interstitial fibrosis and diffuse degenerative change
in cardiac muscle fibers consistent with a cardiomyopathy.
4. Mutation defects in membrane signal transduction and
repair proteins
4.1. Caveolinopathy
Defect caveolin-3 is the molecular cause of LGMD1C.
However, mutated caveolin-3 may also cause 'rippling muscle
disease', and other phenotypes associated with caveolin-3
mutations include distal myopathy with pronounced atrophy of
intrinsic muscles in hands and feet [61,62]. The molecular
pathomechanism of caveolinopathy is not clarified. Based on
the function of the caveolae on the sarcolemma, disruption of
signal transduction through caveolae is thought to be the
consequence of mutant caveolin-3 (Fig. 1A). CAV3 mutations
are dominant, implicating a negative effect of the mutant on the
wild type copies of the protein. Dysferlin seems to interact with
caveolin-3, and dysferlin immunostaining is markedly attenu-
ated in patients who harbor mutations in caveolin-3 [61,63].
4.2. Distal dysferlinopathy
Dysferlin is a sarcolemmal protein with expression also in
the cytoplasm (Fig. 1A). Dysferlin has not been found to have a
role in the dystrophin associated protein complex, although all
its functions are not yet known [64]. Dysferlin, by analogy to
FER-1 gene in C. elegans and by having calcium-binding C2
domains, may have a role in membrane fusion and maintaining
the structural integrity of the sarcolemma [64]. Dysferlin
interaction with caveolin-3 suggests, that one function of
dysferlin may be to subserve signaling functions of caveolae
[63]. Secondary calpain3 defects have also been shown in
patients with dysferlinopathies [65], but the interaction of
calpain-3 with dysferlin remains to be clarified.
New reports demonstrate a cytoplasmic localization of
dysferlin and association with T-tubule system, resulting in
co-precipitating of dysferlin with dihydropyridine receptor
together with caveolin-3 [66].
4.2.1. Molecular genetic findings
The two phenotypes of dysferlinopathy: distal Miyoshi
Myopathy (MM) and LGMD2B occurred with the samemutation in different individuals even within the same family
[67–71]. Why the identical homozygous mutation may cause
different phenotypes within the same family is not clarified.
Numerous different mutations have been reported and they are
widely distributed along the large gene. Newer methodology for
mutation screening using cDNA from muscle has been
described [72].
Not all patients with MM-like phenotype have dysferlino-
pathy. In four families with adult and later onset of symptoms,
linkage to the MM locus 2p was excluded [73]. In two of these
families a genome wide screen suggested linkage to a locus on
chromosome 10 (LOD 2.57). One family was unlinked to both
loci. Thus, the phenotype is apparently genetically hetero-
geneous, and MM might be reserved for the dysferlin mutated
form, whereas others may be termed MM-like phenotypes until
their molecular etiology has been clarified.
4.2.2. Molecular pathogenesis
Recent ultrastructural studies indicate numerous submicron
sized defects in the plasma membrane, replacement of the
plasma membrane by small vesicles, frequently disintegrating
small papillary projections, as well as numerous small
subsarcolemmal vacuoles as early events in the pathology
[74]. These findings support concepts on the role of dysferlin
in maintaining muscle fiber surface membrane integrity and
resealing of continuous minor disruptions of the sarcolemma
in muscle activity. Dysferlin apparently serves multiple
functions and a tempting explanation for the variable clinical
phenotype at onset of the disease would be that individual
genetic backgrounds modify which pathway of dysferlin is
more or less affected. Later in the disease course both the
distal and the LGMD presentations merge and have similar
outcomes.
4.2.3. Clinical findings
In 1977, two sporadic cases of distal myopathy with onset at
the age of 19 and 20 years were reported from the USA [58],
and Miyoshi et al. described a series of similar patients in Japan
[75]. All patients had weakness and atrophy starting in the distal
lower extremities, particularly in the calf muscles (Fig. 4A).
First symptoms were difficulty in climbing stairs, walking
briskly, or running, and inability of patients to hop on one leg
[76,77]. Proximal muscles were only minimally affected at the
onset, as were hand muscles. Distal dysferlinopathy (MM)
shows slow progression towards proximal muscle involvement
and after 10 to 20 years of disease duration there are similarities
with the evolution of the LGMD2B phenotype. Dysferlinopathy
patients presenting with anterior tibial rather than with calf
muscle weakness have also been reported [78], but imaging
studies of these patients revealed marked fatty degeneration also
of the posterior gastrocnemius and soleus muscles [79].
4.2.4. Epidemiology
Since molecular diagnosis for dysferlinopathy became
available by immunohistochemistry and immunoblotting
using anti-dysferlin antibodies, and by direct DNA genetic
analysis, patients with MM have been diagnosed in many
Fig. 4. Legs of a 24-year-old male patient with dysferlin mutation showing
clinically atrophic calf muscles on the left side (A). Low field MRI muscle
imaging in 32-year-old male patient with dysferlin mutations causing total
replacement of posterior calf muscle bilaterally (B).
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worldwide with a frequency of about 1–2/106.
4.2.5. Laboratory findings and muscle pathology
MM patients have very high serum CK values 10–100 fold
the upper normal level [76,77,80], and this high leakage of CK
is present even at preclinical stages [76]. EMG shows increased
insertional activity, fibrillation potentials and abundant small
motor unit potentials with early recruitment [75–77]. Muscle
imaging with CT or MRI give clear insight in the involvement
of different muscles during the disease process, and can also be
used for assessment of individuals at risk (Fig. 4B).
Muscle biopsy shows nonspecific myopathic/dystrophic
features with abundant necrotic fibers, regenerating fibers,
abnormal variation in fiber size, and later connective tissue
increase [76]. In many dysferlinopathy biopsies inflammatory
infiltrates have been observed [84], and dysferlinopathy has
been confused with polymyositis on many occasions. Immu-
nohistochemistry and immunoblotting with anti-dysferlin anti-bodies showing absent dysferlin has become the gold standard
for pathological assessment and diagnosis. [74]. Immunoblots
of MM muscle extracts accurately reveal dysferlin deficiency,
whereas immunostaining of cryostat sections of MM muscle is
less reliable. Currently available anti-dysferlin antibodies may
stain the normal muscle surface only weakly, even at high
concentration. On the other hand dysferlin may be non-
specifically over-expressed in regenerative fibers in any
myopathic disorder (personal comment).
5. Distal muscular dystrophy caused by sarcoplasmic
enzyme defects
5.1. GNE-mutated distal myopathy with rimmed vacuoles
(DMRV)
GNE is a dual epimerase/kinase enzyme and the rate-limiting
enzyme in the sialic acid biosynthetic pathway [85]. (see the
corresponding Chapter for GNE-details).
5.1.1. Molecular genetic findings
After the gene was identified in autosomal recessive
quadriceps sparing myopathy/hereditary inclusion body myo-
pathy AR-hIBM, DMRV in Japanese patients proved to be
caused by mutations in the same GNE-gene, confirming these
are allelic disorders [86]. Many different mutations in GNE
have been reported in Japanese DMRV patient [87,88], and one
of them, V572L, is more common and accounts for a founder
effect [86].
5.1.2. Molecular pathogenesis
Mechanistic explanation of why the double enzyme defects
cause rimmed vacuolar myofibrillar degeneration is still
lacking. However, defect sialyation is one major hypothesis
and experimental cell studies have shown encouraging results in
reverting the phenotype by adding sialic acid (Nishino personal
communication). Further experiments are ongoing including
mouse models. For more details, see further the Chapter on
hIBM.
5.1.3. Clinical findings
Distal myopathy patients with onset in early adulthood of
weakness in the lower legs, typically in the anterior compart-
ment, causing foot drop were reported by Nonaka et al. [89].
Progression to posterior compartment and proximal muscles
was always present and major disability usually was the
outcome after 10–15 years of disease duration. Intrinsic
muscles were also involved. DMRV followed an autosomal
recessive inheritance pattern.
5.1.4. Laboratory findings and muscle pathology
CK values are normal or slightly elevated in DMRV
patients and EMG shows abundant small motor units
potentials and spontaneous discharges including positive
sharp waves and fibrillations [89,90]. By definition DMRV
is characterized by rimmed vacuoles in muscle fibres [90,91].
Necrotic fibers may or may not be present. Ubiquitin
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lysosomal degradative activity as another part of the
degradative pathogenesis [92,93]. Finally, tubulofilamentous
inclusions like those occurring in sporadic IBM were also
observed in DMRV [94]. These morphological studies were
mostly done before the gene defect in DMRV was known
and, thus, it is not known whether all studied patients were
GNE-mutated cases.
6. Distal dystrophies with unknown molecular defects
6.1. Welander distal myopathy
In her thesis in 1951 Welander described 249 patients with
this disease [95]. The initial symptoms were clumsiness in
precise finger movements, beginning as extensor weakness in
the thumb or index fingers and spreading to the other fingers.
Distal leg involvement occurred later, with stumbling, difficulty
in walking, and, eventually, inability to stand on the heels or
development of a steppage gait. In a minority symptoms may
start in the lower limbs. These early clinical observations have
been documented 50 years later by muscle imaging [96].
Coldness of the hands and feet occurred in 90% of patients and
the disease shows autosomal dominant inheritance.
The possibility of a neurogenic component in WDM was
first considered by Welander [95]. Mild neurogenic features
were later detailed by Borg and coworkers who found
abnormalities of sensory function and sural nerve histology
[97], but no abnormalities of sensory nerve conduction
velocities, nor any neurogenic findings in 8 anterior tibial
muscle biopsies in young and middle-aged adults with early
symptoms [98].
6.1.1. Epidemiology
There are no exact studies on epidemiology of WDM, but
estimates based on patient numbers at different regional
neuromuscular centers indicate a prevalence about 5/105 in
Sweden (Edström, personal communication). Recent data
emerged from Finland where WDM has been identified in
several families [99].
6.1.2. Molecular genetic findings
Genetic studies in well defined WDM families determined
linkage of the disease to a locus on chromosome 2p13 close to,
but outside the dysferlin locus [100,101]. All known genes in
the linked locus have been sequenced without identification of
the causative gene [102]. All WDM patients in Sweden and
Finland carry the same haplotype at the locus indicating one
single common founder mutation [99,100]. In one of the
families included in the linkage studies, one patient was
homozygous for the linked haplotype and he, indeed, displayed
a much more severe myopathy compared to typical WDM
[100].
6.1.3. Laboratory findings and muscle pathology
Serum CK may be normal or up to a threefold elevated in
WDM patients [103]. EMG studies in WDM patients showbrief, short and polyphasic motor unit potentials, and in severely
affected muscles a decreased number of motor unit potentials.
Spontaneous electrical activity at rest, fibrillation potentials, and
discharges have been reported [103]. Computed tomography
(CT) and magnetic resonance imaging (MRI) both show fatty
degeneration of affected muscles with replacement lesions in
the anterior compartment and frequently in the soleus and
gastrocnemius muscles in the leg [96,104].
In the affected muscles rimmed vacuoles were found in
atrophic fibers of both fiber types. On electron microscopy
tibialis anterior specimens revealed autophagic vacuoles
harboring dense bodies, myelin figures, and tubulofilamentous
inclusions [97,98].
6.2. Other distal myopathies—single families
Several single families have been reported with distal
myopathy distinct to the known entities as shown by linkage
exclusion to established loci or by linkage assignment to
specific new loci. These are comprehensively reviewed else-
where [1].
7. Distal phenotypes in other myopathies
The disorders described above were all reported as distal
myopathies. However, there are many disorders which can
present with a distal phenotype that were classified or
reported under different headings. These are important when
discussing phenotypes versus molecular pathogenesis, and
they illustrate the further development of molecular genetics
serving as a new basis for classification of myopathies.
Moreover, molecular genetics has disclosed allelic disorders
or even identical gene defects that may present with highly
variable phenotypes [27]. Because of noteworthy general
aspects on molecular pathomechanisms and selective muscle
involvement, two entities are separately notified.
7.1. Myotonic dystrophy type 1
Myotonic dystrophy type 1 (Steinert's disease) is world-
wide the most common cause of a distal muscular dystrophy
phenotype, not classified so because of the overt multi-system
character of the disease. The molecular biological reason of
why distal muscles are preferentially involved is not known.
The repeat expansion underlying the disease alters the
splicing machinery of gene transcription. At present a dozen
different genes are shown to be affected and the list may
grow to hundreds or more, but which of the abnormally
spliced genes are responsible the distal muscle involvement is
unknown [105].
7.2. Oculopharyngodistal myopathy
The extraocular muscles are rarely affected in muscular
dystrophy. The exceptions are mitochondrial muscle disorders
such as PEO, and oculopharyngeal muscular dystrophy
(OPMD) which is caused by a short repeat expansion in the
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myopathy and prominent oculopharyngeal weakness, in one
associated with cardiomyopathy, have been reported [106,107].
In other families the trait seemed to be autosomal recessive
[108,109].
7.3. Other disorders with occasional distal presentation
Rare instances of distal weakness have been described in
chronic polymyositis [110]. Inclusion body myositis (s-IBM)
often presents with anterior compartment leg or forearm
weakness [111].
Patients with either facioscapulohumeral dystrophy (FSHD)
or scapuloperoneal syndromes, presenting with anterior tibial
muscle weakness before facial or shoulder weakness is evident,
are not very rare and may cause diagnostic confusion. In FSHD
isolated calf muscle involvement has been reported rarely.
Mutation analysis is mandatory to identify ‘sporadic’ cases of
FSHD [112]. Most recently, the increased expression of FGR1
gene that follows the FSHD mutation, was shown to also alter
splicing machinery [113]. In other disorders rare cases may have
a distal presentation such as: centronuclear myopathy [114],
debrancher enzyme deficiency myopathy (glycogenosis type 3)
[115], phosphorylase b kinase deficiency [116], and lipid
storage myopathies [117]. A distal phenotype can also occur
secondary to nephropathic cystinosis [118].References
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